Gregory Vidal, MD, PhD

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.